EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary

Sumit Verma, Alejandro Hughes iD, Nicole M Engel-Nitz, Christina Steiger, Shreekant Parasuraman, Milind Javle iD, Sunyoung S Lee, Fen Saj, Michael Blecker

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Sumit Verma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Corp., Wilmington, DE, United States. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Pyrimidines, Bile Duct Neoplasms, Neoplasms, Unknown Primary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited evidence regarding the economic burden, treatment patterns, and overall survival (OS) of patients with cholangiocarcinoma (CCA) and cancer of unknown primary (CUP) who initiated the FGFR inhibitor pemigatinib. Patients and Methods We used the Komodo Healthcare Map to identify patients with CCA who initiated pemigatinib between 4/17/2020 and 5/31/2023. Follow-up began at initiation and lasted ≥ 1 month. Outcomes included health care resource utilization (HCRU), costs, treatment patterns, and OS.

Results

Two hundred twenty-one patients were included: 78 patients (35.3%) with CUP (median follow-up, 5.9 months) and 143 patients (64.7%) without CUP (median follow-up, 7.3 months). Pemigatinib was similarly well-tolerated in CUP vs non-CUP. Discontinuation was observed in 43.6% vs 49.0% (P = .445). Medication possession ratio ≥ 0.80 was achieved by 71.6% vs 67.2% (P = .504). CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P = .066). Median OS was significantly shorter with CUP (10.2 vs 30.7 months).

Conclusion

Although pemigatinib was similarly well-tolerated regardless of CUP status, patients with CUP incurred greater ambulatory burden and had poorer OS. Patients with CUP were more likely to have evidence of metastatic disease at pemigatinib initiation, which may help explain these results. With the advent of targeted treatments for gene-altered CCA, reflexive genomic testing should be encouraged for all patients with CUP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaPyrimidinesBile Duct NeoplasmsNeoplasms, Unknown PrimaryMorpholinesPyrrolesHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

FGFRbiliary tract cancercancer of unknown primarycholangiocarcinomahealth care costshealth care resource utilization

Substanzen

PyrimidinespemigatinibMorpholinesPyrroles

Autor:innen und Institutionen

  • Incyte Corp., Wilmington, DE, United States.
  • Optum, Inc., Eden Prairie, MN, United States.
  • Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

ORCID-Profile: Alejandro Hughes, Milind Javle

Förderung

  • Incyte Corp

Zitieren

APA

Verma, S., Hughes, A., Engel-Nitz, N. M., Steiger, C., Parasuraman, S., Javle, M., Lee, S. S., Saj, F., & Blecker, M. (2025). Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary. The Oncologist. https://doi.org/10.1093/oncolo/oyaf352

Vancouver

Verma S, Hughes A, Engel-Nitz NM, Steiger C, Parasuraman S, Javle M, et al. Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary. The Oncologist. 2025. doi:10.1093/oncolo/oyaf352

BibTeX
@article{Verma2025,
  author = {Verma, Sumit and Hughes, Alejandro and Engel-Nitz, Nicole M and Steiger, Christina and Parasuraman, Shreekant and Javle, Milind and Lee, Sunyoung S and Saj, Fen and Blecker, Michael},
  title = {Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf352}
}
Kostenlos starten →